Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	transmembrane-ephrin receptor activity	EPHB3 EPHA1 EPHA8	4.00e-05	15	91	3	GO:0005005
GeneOntologyMolecularFunction	ephrin receptor activity	EPHB3 EPHA1 EPHA8	8.42e-05	19	91	3	GO:0005003
GeneOntologyMolecularFunction	transmembrane receptor protein tyrosine kinase activity	EPHB3 ALK EPHA1 EPHA8	2.21e-04	65	91	4	GO:0004714
Domain	RECEPTOR_TYR_KIN_V_2	EPHB3 EPHA1 EPHA8	3.08e-05	14	84	3	PS00791
Domain	RECEPTOR_TYR_KIN_V_1	EPHB3 EPHA1 EPHA8	3.08e-05	14	84	3	PS00790
Domain	Eph_TM	EPHB3 EPHA1 EPHA8	3.08e-05	14	84	3	IPR027936
Domain	Tyr_kinase_rcpt_V_CS	EPHB3 EPHA1 EPHA8	3.08e-05	14	84	3	IPR001426
Domain	EPH_lbd	EPHB3 EPHA1 EPHA8	3.08e-05	14	84	3	SM00615
Domain	Ephrin_lbd	EPHB3 EPHA1 EPHA8	3.08e-05	14	84	3	PF01404
Domain	EphA2_TM	EPHB3 EPHA1 EPHA8	3.08e-05	14	84	3	PF14575
Domain	Tyr_kinase_ephrin_rcpt	EPHB3 EPHA1 EPHA8	3.08e-05	14	84	3	IPR016257
Domain	Ephrin_rcpt_lig-bd_dom	EPHB3 EPHA1 EPHA8	3.08e-05	14	84	3	IPR001090
Domain	EPH_LBD	EPHB3 EPHA1 EPHA8	3.08e-05	14	84	3	PS51550
Domain	REJ	PKD1 PKD1L2	1.19e-04	4	84	2	PS51111
Domain	REJ_dom	PKD1 PKD1L2	1.19e-04	4	84	2	IPR014010
Domain	Ephrin_rec_like	EPHB3 EPHA1 EPHA8	1.88e-04	25	84	3	SM01411
Domain	Tyr-kin_ephrin_A/B_rcpt-like	EPHB3 EPHA1 EPHA8	1.88e-04	25	84	3	IPR011641
Domain	Sec23/24_helical_dom	SEC23B SEC23A	2.96e-04	6	84	2	IPR006900
Domain	PKD/REJ-like	PKD1 PKD1L2	2.96e-04	6	84	2	IPR002859
Domain	Sec23_24_beta_S	SEC23B SEC23A	2.96e-04	6	84	2	IPR012990
Domain	zf-Sec23_Sec24	SEC23B SEC23A	2.96e-04	6	84	2	PF04810
Domain	Sec23_trunk	SEC23B SEC23A	2.96e-04	6	84	2	PF04811
Domain	Sec23_helical	SEC23B SEC23A	2.96e-04	6	84	2	PF04815
Domain	Sec23_BS	SEC23B SEC23A	2.96e-04	6	84	2	PF08033
Domain	REJ	PKD1 PKD1L2	2.96e-04	6	84	2	PF02010
Domain	Sec23/24_trunk_dom	SEC23B SEC23A	2.96e-04	6	84	2	IPR006896
Domain	Znf_Sec23_Sec24	SEC23B SEC23A	2.96e-04	6	84	2	IPR006895
Domain	C_TYPE_LECTIN_1	PLA2R1 PKD1 PKD1L2 KLRG1	4.64e-04	80	84	4	PS00615
Domain	Lectin_C	PLA2R1 PKD1 PKD1L2 KLRG1	5.59e-04	84	84	4	PF00059
Domain	CLECT	PLA2R1 PKD1 PKD1L2 KLRG1	5.59e-04	84	84	4	SM00034
Domain	C_TYPE_LECTIN_2	PLA2R1 PKD1 PKD1L2 KLRG1	5.84e-04	85	84	4	PS50041
Domain	C-type_lectin-like	PLA2R1 PKD1 PKD1L2 KLRG1	6.11e-04	86	84	4	IPR001304
Domain	TyrKc	EPHB3 ALK EPHA1 EPHA8	6.66e-04	88	84	4	SM00219
Domain	Tyr_kinase_cat_dom	EPHB3 ALK EPHA1 EPHA8	6.66e-04	88	84	4	IPR020635
Domain	PROTEIN_KINASE_TYR	EPHB3 ALK EPHA1 EPHA8	9.60e-04	97	84	4	PS00109
Domain	Tyr_kinase_AS	EPHB3 ALK EPHA1 EPHA8	9.60e-04	97	84	4	IPR008266
Domain	-	PLA2R1 PKD1 PKD1L2 KLRG1	9.60e-04	97	84	4	3.10.100.10
Domain	C-type_lectin-like/link	PLA2R1 PKD1 PKD1L2 KLRG1	1.04e-03	99	84	4	IPR016186
Domain	PKD_channel	PKD1 PKD1L2	1.07e-03	11	84	2	PF08016
Domain	PKD1_2_channel	PKD1 PKD1L2	1.07e-03	11	84	2	IPR013122
Domain	CTDL_fold	PLA2R1 PKD1 PKD1L2 KLRG1	1.38e-03	107	84	4	IPR016187
Domain	Gelsolin	SEC23B SEC23A	1.76e-03	14	84	2	PF00626
Domain	Gelsolin-like_dom	SEC23B SEC23A	1.76e-03	14	84	2	IPR007123
Domain	MAM_1	ZAN ALK	2.30e-03	16	84	2	PS00740
Domain	Pkinase_Tyr	EPHB3 ALK EPHA1 EPHA8	2.74e-03	129	84	4	PF07714
Domain	MAM	ZAN ALK	2.92e-03	18	84	2	PF00629
Domain	LH2	PKD1 PKD1L2	2.92e-03	18	84	2	SM00308
Domain	MAM_dom	ZAN ALK	2.92e-03	18	84	2	IPR000998
Domain	MAM_2	ZAN ALK	2.92e-03	18	84	2	PS50060
Domain	Ser-Thr/Tyr_kinase_cat_dom	EPHB3 ALK EPHA1 EPHA8	3.49e-03	138	84	4	IPR001245
Domain	SAM_1	EPHB3 EPHA1 EPHA8	3.56e-03	68	84	3	PF00536
Domain	PLAT	PKD1 PKD1L2	3.97e-03	21	84	2	PS50095
Domain	-	PKD1 PKD1L2	3.97e-03	21	84	2	2.60.60.20
Domain	PLAT	PKD1 PKD1L2	3.97e-03	21	84	2	PF01477
Domain	PLAT/LH2_dom	PKD1 PKD1L2	3.97e-03	21	84	2	IPR001024
Domain	-	EPHB3 EPHA1 EPHA8	4.35e-03	73	84	3	2.60.120.260
Pubmed	Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors.	EML4 ALK	7.38e-06	2	95	2	27811184
Pubmed	Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer.	EML4 ALK	7.38e-06	2	95	2	21356191
Pubmed	Internalization and down-regulation of the ALK receptor in neuroblastoma cell lines upon monoclonal antibodies treatment.	CBL ALK	7.38e-06	2	95	2	22479414
Pubmed	Clinicopathological and Prognostic Significance of the EML4-ALK Translocation and IGFR1, TTF1, Napsin A Expression in Patients with Lung Adenocarcinoma.	EML4 ALK	7.38e-06	2	95	2	32876329
Pubmed	Malignant pleural mesothelioma with an EML4-ALK fusion: Expect the unexpected!	EML4 ALK	7.38e-06	2	95	2	35074700
Pubmed	A rare case of an EML4-ALK-rearranged lung adenocarcinoma missed by in situ-hybridization but detected by RT-PCR.	EML4 ALK	7.38e-06	2	95	2	25028527
Pubmed	EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.	EML4 ALK	7.38e-06	2	95	2	18594010
Pubmed	EML4-ALK induces epithelial-mesenchymal transition consistent with cancer stem cell properties in H1299 non-small cell lung cancer cells.	EML4 ALK	7.38e-06	2	95	2	25735977
Pubmed	EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.	EML4 ALK	7.38e-06	2	95	2	22124476
Pubmed	Second Primary Lung Adenocarcinoma Harboring EML4-ALK After Surgically Resected EGFR Positive Lung Adenocarcinoma.	EML4 ALK	7.38e-06	2	95	2	26704814
Pubmed	EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues.	EML4 ALK	7.38e-06	2	95	2	19147828
Pubmed	Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells.	EML4 ALK	7.38e-06	2	95	2	26517679
Pubmed	Preselection based on clinical characteristics in German non-small-cell lung cancer patients screened for EML4-ALK translocation.	EML4 ALK	7.38e-06	2	95	2	24346098
Pubmed	Phase-separated foci of EML4-ALK facilitate signalling and depend upon an active kinase conformation.	EML4 ALK	7.38e-06	2	95	2	34661367
Pubmed	Circular RNA F-circEA-2a derived from EML4-ALK fusion gene promotes cell migration and invasion in non-small cell lung cancer.	EML4 ALK	7.38e-06	2	95	2	30236141
Pubmed	A novel mechanism of EML4-ALK rearrangement mediated by chromothripsis in a patient-derived cell line.	EML4 ALK	7.38e-06	2	95	2	25144242
Pubmed	Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.	EML4 ALK	7.38e-06	2	95	2	18927303
Pubmed	EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas.	EML4 ALK	7.38e-06	2	95	2	18242762
Pubmed	Cloning and functional characterization of mammalian homologues of the COPII component Sec23.	SEC23B SEC23A	7.38e-06	2	95	2	8898360
Pubmed	Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.	EML4 ALK	7.38e-06	2	95	2	18593892
Pubmed	Expanded Circulating Tumor Cells from a Patient with ALK-Positive Lung Cancer Present with EML4-ALK Rearrangement Along with Resistance Mutation and Enable Drug Sensitivity Testing: A Case Study.	EML4 ALK	7.38e-06	2	95	2	27507192
Pubmed	Reelin signals survival through Src-family kinases that inactivate BAD activity.	RELN BAD	7.38e-06	2	95	2	17696989
Pubmed	EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers.	EML4 ALK	7.38e-06	2	95	2	18414414
Pubmed	The impact of the ALK fusion variant on clinical outcomes in EML4-ALK patients with NSCLC: a systematic review and meta-analysis.	EML4 ALK	7.38e-06	2	95	2	34783600
Pubmed	The prevalence of ALK rearrangement in pulmonary adenocarcinomas in an unselected Caucasian population from a defined catchment area: impact of smoking.	EML4 ALK	7.38e-06	2	95	2	27943404
Pubmed	Investigation on the prognostic impact of concurrent genomic alterations in crizotinib-treated EML4-ALK-rearranged advanced non-small cell lung cancer patients.	EML4 ALK	7.38e-06	2	95	2	32563740
Pubmed	Effective enrichment strategy for EML4-ALK fusion gene screening in patients with non-small cell lung cancer.	EML4 ALK	7.38e-06	2	95	2	24388371
Pubmed	Circular RNA F-circEA produced from EML4-ALK fusion gene as a novel liquid biopsy biomarker for non-small cell lung cancer.	EML4 ALK	7.38e-06	2	95	2	29628502
Pubmed	New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.	EML4 ALK	7.38e-06	2	95	2	29199691
Pubmed	Clinicopathological features of younger (aged ≤ 50 years) lung adenocarcinoma patients harboring the EML4-ALK fusion gene.	EML4 ALK	7.38e-06	2	95	2	29517858
Pubmed	Malignant pleural effusion cell blocks are substitutes for tissue in EML4-ALK rearrangement detection in patients with advanced non-small-cell lung cancer.	EML4 ALK	7.38e-06	2	95	2	27060609
Pubmed	Functions of the COPII gene paralogs SEC23A and SEC23B are interchangeable in vivo.	SEC23B SEC23A	7.38e-06	2	95	2	30065114
Pubmed	Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target.	EML4 ALK	7.38e-06	2	95	2	24633422
Pubmed	Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer.	EML4 ALK	7.38e-06	2	95	2	28039177
Pubmed	Pulmonary inflammatory myofibroblastic tumor harboring EML4-ALK fusion gene.	EML4 ALK	7.38e-06	2	95	2	24277751
Pubmed	Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs.	EML4 ALK	7.38e-06	2	95	2	26755435
Pubmed	Effective RNA Knockdown Using CRISPR-Cas13a and Molecular Targeting of the EML4-ALK Transcript in H3122 Lung Cancer Cells.	EML4 ALK	7.38e-06	2	95	2	33255340
Pubmed	Oncogenic EML4-ALK assemblies suppress growth factor perception and modulate drug tolerance.	EML4 ALK	7.38e-06	2	95	2	39488530
Pubmed	Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer.	EML4 ALK	7.38e-06	2	95	2	26544515
Pubmed	Non-small cell lung cancer patients with EML4-ALK fusion gene are insensitive to cytotoxic chemotherapy.	EML4 ALK	7.38e-06	2	95	2	24982409
Pubmed	EML4-ALK fusion lung cancer: a rare acquired event.	EML4 ALK	7.38e-06	2	95	2	18320074
Pubmed	EML4-ALK translocation in both metachronous second primary lung sarcomatoid carcinoma and lung adenocarcinoma: a case report.	EML4 ALK	7.38e-06	2	95	2	23664446
Pubmed	EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.	EML4 ALK	7.38e-06	2	95	2	18166835
Pubmed	Identification of anaplastic lymphoma kinase fusions in clear cell renal cell carcinoma.	EML4 ALK	7.38e-06	2	95	2	32020234
Pubmed	Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance.	EML4 ALK	7.38e-06	2	95	2	34391065
Pubmed	Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.	EML4 ALK	7.38e-06	2	95	2	19737969
Pubmed	Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: a meta-analysis.	EML4 ALK	7.38e-06	2	95	2	25706305
Pubmed	EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer.	EML4 ALK	7.38e-06	2	95	2	29363116
Pubmed	A polymorphism at the microRNA binding site in the 3' untranslated region of C14orf101 is associated with non-Hodgkin lymphoma overall survival.	TMEM260 RYR3	7.38e-06	2	95	2	24831772
Pubmed	Disruption of segmental neural crest migration and ephrin expression in delta-1 null mice.	EPHB3 EPHA1 EPHA8	1.31e-05	17	95	3	12217323
Pubmed	Multiple roles of EPH receptors and ephrins in neural development.	EPHB3 EPHA1 EPHA8	2.18e-05	20	95	3	11256076
Pubmed	The ephrins and Eph receptors in neural development.	EPHB3 EPHA1 EPHA8	2.18e-05	20	95	3	9530499
Pubmed	Eph receptors and ephrins: effectors of morphogenesis.	EPHB3 EPHA1 EPHA8	2.18e-05	20	95	3	10207129
Pubmed	The Eph family receptors and ligands.	EPHB3 EPHA1 EPHA8	2.18e-05	20	95	3	9576626
Pubmed	An unusual fusion gene EML4-ALK in a patient with congenital mesoblastic nephroma.	EML4 ALK	2.21e-05	3	95	2	34378283
Pubmed	EGFR alterations and EML4-ALK rearrangement in primary adenocarcinoma of the urinary bladder.	EML4 ALK	2.21e-05	3	95	2	23887300
Pubmed	Simple and rapid in vivo generation of chromosomal rearrangements using CRISPR/Cas9 technology.	EML4 ALK	2.21e-05	3	95	2	25456124
Pubmed	Genetic analysis of the role of Eph receptors in the development of the mammalian nervous system.	EPHB3 EPHA8	2.21e-05	3	95	2	9321682
Pubmed	Ryanodine receptors are targeted by anti-apoptotic Bcl-XL involving its BH4 domain and Lys87 from its BH3 domain.	BAD RYR3	2.21e-05	3	95	2	25872771
Pubmed	Effects of SMYD2-mediated EML4-ALK methylation on the signaling pathway and growth in non-small-cell lung cancer cells.	EML4 ALK	2.21e-05	3	95	2	28370702
Pubmed	Serum carcinoembryonic antigen levels before initial treatment are associated with EGFR mutations and EML4- ALK fusion gene in lung adenocarcinoma patients.	EML4 ALK	2.21e-05	3	95	2	24935562
Pubmed	ALK translocation detection in non-small cell lung cancer cytological samples obtained by TBNA or EBUS-TBNA.	EML4 ALK	2.21e-05	3	95	2	25757141
Pubmed	Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.	EML4 ALK	2.21e-05	3	95	2	26019170
Pubmed	Clinical profile and outcomes of patients with Stage IV adenocarcinoma of lung: A tertiary cancer center experience.	EML4 ALK	2.21e-05	3	95	2	29199690
Pubmed	miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.	EML4 ALK	2.21e-05	3	95	2	30791979
Pubmed	Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells.	EML4 ALK	2.21e-05	3	95	2	24952482
Pubmed	[Lung cancer in never smoker: Epidemiology, molecular profiles and treatment].	EML4 ALK	2.21e-05	3	95	2	21420271
Pubmed	EML4-ALK induces cellular senescence in mortal normal human cells and promotes anchorage-independent growth in hTERT-transduced normal human cells.	EML4 ALK	2.21e-05	3	95	2	33761896
Pubmed	A ligand-inducible anaplastic lymphoma kinase chimera is endocytosis impaired.	CBL ALK	2.21e-05	3	95	2	14691459
Pubmed	Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations.	EML4 ALK	2.21e-05	3	95	2	22736493
Pubmed	A causal link from ALK to hexokinase II overexpression and hyperactive glycolysis in EML4-ALK-positive lung cancer.	EML4 ALK	2.21e-05	3	95	2	27132509
Pubmed	Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion.	EML4 ALK	2.21e-05	3	95	2	30107055
Pubmed	A novel break site of EML4-ALK report and a rare PRKAR1A-ALK report analyzed by different ALK detection platforms in non-small cell lung cancer patients.	EML4 ALK	2.21e-05	3	95	2	34490727
Pubmed	Unified nomenclature for Eph family receptors and their ligands, the ephrins. Eph Nomenclature Committee.	EPHB3 EPHA1 EPHA8	2.53e-05	21	95	3	9267020
Pubmed	Eph receptors and ephrins demarcate cerebellar lobules before and during their formation.	EPHB3 EPHA1 EPHA8	2.53e-05	21	95	3	10495276
Pubmed	Developmental expression of Eph and ephrin family genes in mammalian small intestine.	EPHB3 EPHA1 EPHA8	2.53e-05	21	95	3	20112066
Pubmed	Roles of Eph receptors and ephrins in segmental patterning.	EPHB3 EPHA1 EPHA8	2.53e-05	21	95	3	11128993
Pubmed	Eph receptors and ephrins: regulators of guidance and assembly.	EPHB3 EPHA1 EPHA8	2.53e-05	21	95	3	10730216
Pubmed	Eph receptors and their ephrin ligands are expressed in developing mouse pancreas.	EPHB3 EPHA1 EPHA8	3.83e-05	24	95	3	16446123
Pubmed	Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.	EML4 ALK	4.41e-05	4	95	2	19667264
Pubmed	Structure and Conformational Dynamics of the Human Spliceosomal Bact Complex.	PRPF8 SRRM2	4.41e-05	4	95	2	29361316
Pubmed	TANGO1/cTAGE5 receptor as a polyvalent template for assembly of large COPII coats.	SEC23B SEC23A	4.41e-05	4	95	2	27551091
Pubmed	Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.	EML4 ALK	4.41e-05	4	95	2	18083107
Pubmed	Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer.	EML4 ALK	4.41e-05	4	95	2	23341890
Pubmed	Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.	EML4 ALK	4.41e-05	4	95	2	20624322
Pubmed	Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component.	EML4 ALK	4.41e-05	4	95	2	21036415
Pubmed	EML4-ALK V3 oncogenic fusion proteins promote microtubule stabilization and accelerated migration through NEK9 and NEK7.	EML4 ALK	4.41e-05	4	95	2	32184261
Pubmed	c-Cbl regulates MICA- but not ULBP2-induced NKG2D down-modulation in human NK cells.	MICA CBL	4.41e-05	4	95	2	24846123
Pubmed	ALG-2 attenuates COPII budding in vitro and stabilizes the Sec23/Sec31A complex.	SEC23B SEC23A	4.41e-05	4	95	2	24069399
Pubmed	Expression of the Grb2-related protein of the lymphoid system in B cell subsets enhances B cell antigen receptor signaling through mitogen-activated protein kinase pathways.	GRAP2 CBL	7.34e-05	5	95	2	12496419
Pubmed	Leukemic transformation in mice expressing a NUP98-HOXD13 transgene is accompanied by spontaneous mutations in Nras, Kras, and Cbl.	NUP98 CBL	7.34e-05	5	95	2	18566322
Pubmed	Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients.	EML4 ALK	7.34e-05	5	95	2	23919423
Pubmed	A YAC contig containing the reeler locus with preliminary characterization of candidate gene fragments.	RELN ARMC10	7.34e-05	5	95	2	7607678
Pubmed	The protein tyrosine kinase family of the human genome.	EPHB3 ALK EPHA1 EPHA8	8.14e-05	83	95	4	11114734
Pubmed	Interactome analysis reveals that lncRNA HULC promotes aerobic glycolysis through LDHA and PKM2.	PDPR NUP98 PRPF8 SEC23B SEC23A	8.27e-05	161	95	5	32572027
Pubmed	Identification of genes related to Parkinson's disease using expressed sequence tags.	COMMD1 MICA CCNQ KLRG1	8.93e-05	85	95	4	17213182
Pubmed	Yeast two-hybrid screens imply that GGNBP1, GGNBP2 and OAZ3 are potential interaction partners of testicular germ cell-specific protein GGN1.	SEC23B SEC23A	1.10e-04	6	95	2	15642376
Pubmed	Sec24 proteins and sorting at the endoplasmic reticulum.	SEC23B SEC23A	1.10e-04	6	95	2	10075675
Pubmed	The SAM domains of Anks family proteins are critically involved in modulating the degradation of EphA receptors.	CBL EPHA8	1.10e-04	6	95	2	20100865
Pubmed	Failure to ubiquitinate c-Met leads to hyperactivation of mTOR signaling in a mouse model of autosomal dominant polycystic kidney disease.	PKD1 CBL	1.10e-04	6	95	2	20852388
Interaction	ALK interactions	NUDT19 EPHB3 LRBA CBL ALK SEC23B SEC23A EPHA1 EPHA8	2.85e-06	271	88	9	int:ALK
Interaction	EPHA8 interactions	NUDT19 EPHB3 CBL ALK SEC23B SEC23A EPHA8	9.24e-06	169	88	7	int:EPHA8
GeneFamily	Fibronectin type III domain containing\|Sterile alpha motif domain containing\|EPH receptors	EPHB3 EPHA1 EPHA8	1.30e-05	14	61	3	1095
GeneFamily	Glycosyltransferase family 2	B3GNTL1 HAS1	1.67e-04	6	61	2	428
GeneFamily	Fibronectin type III domain containing	EPHB3 PTPRH EPHA1 EPHA8	2.08e-03	160	61	4	555
GeneFamily	Nudix hydrolase family	NUDT19 NUDT22	2.95e-03	24	61	2	667
GeneFamily	Sterile alpha motif domain containing	EPHB3 EPHA1 EPHA8	3.27e-03	88	61	3	760
ToppCell	10x3'2.3-week_14-16-Myeloid_neutrophil-granulo-eo/baso/mast-eosinophil\|week_14-16 / cell types per 3 fetal stages;per 3',per 5'	NAALADL1 HS6ST1 GRAP2 KLRG1 CDH7 SOAT2	2.36e-06	179	95	6	810972561d1ae5a68389b54ceeac7a49890513a4
ToppCell	droplet-Heart-4Chambers-21m-Endothelial-leukocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RELN ACAD10 FAM217A KLRG1 RYR3 KLHL4	2.86e-06	185	95	6	bb5a4cf93534b9bcd0923f314c389d571e91e7f8
ToppCell	10x3'2.3-week_17-19-Myeloid_neutrophil-granulo-eo/baso/mast-mast_cell\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	NAALADL1 HS6ST1 GRAP2 KLRG1 SOAT2 RYR3	3.54e-06	192	95	6	758ca0dacf313787effda36e6d1adb809e5b3a4e
ToppCell	10x3'2.3-week_17-19-Myeloid_neutrophil-granulo-eo/baso/mast\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	NAALADL1 HS6ST1 GRAP2 KLRG1 SOAT2 RYR3	3.87e-06	195	95	6	fbedb9978ded857fd35c2a8664f7579f42edaa36
ToppCell	3'_v3-blood-Lymphocytic_T_CD4-T_CD4/CD8\|blood / Manually curated celltypes from each tissue	EML4 LRBA CENATAC FAM186B C2orf72	1.05e-05	135	95	5	ae2d3a42e567b5bade304c0caa497eb725be3565
Disease	congenital dyserythropoietic anemia type II (implicated_via_orthology)	SEC23B SEC23A	8.79e-06	2	88	2	DOID:0111401 (implicated_via_orthology)
Disease	craniolenticulosutural dysplasia (implicated_via_orthology)	SEC23B SEC23A	8.79e-06	2	88	2	DOID:0070307 (implicated_via_orthology)
Disease	Huntington Disease	RELN NRSN1 OGG1	1.69e-05	17	88	3	C0020179
Disease	disease progression measurement	METTL4 ADCY5 SOAT2 RYR3	3.38e-05	61	88	4	EFO_0008336
Disease	Roberts syndrome (implicated_via_orthology)	SEC23B SEC23A	5.26e-05	4	88	2	DOID:5325 (implicated_via_orthology)
Disease	Gastrointestinal Hemorrhage	RELN NRSN1	3.12e-04	9	88	2	C0017181
Disease	n-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase 2 measurement	B3GNTL1 COMMD1	3.12e-04	9	88	2	EFO_0801817
Disease	Adenocarcinoma of lung (disorder)	EML4 IRAK1 OGG1 ALK EPHA8	3.87e-04	206	88	5	C0152013
Disease	pancreatic hormone measurement	FRMPD2 FRMPD2B	3.90e-04	10	88	2	EFO_0020621
Disease	alkaline phosphatase measurement	ZHX3 HS6ST1 PKD1 ACAD10 LRBA NRSN1 FUT6 ADCY5 MIR22HG EPHA8	8.84e-04	1015	88	10	EFO_0004533
Disease	Hodgkin Disease	RELN NRSN1	1.95e-03	22	88	2	C0019829
Disease	Kallmann Syndrome	HS6ST1 ARNT2	2.73e-03	26	88	2	C0162809

Protein segments in the cluster

Peptide	Gene	Start	Entry
SGWNSWVFGILNISR	nan	101	A4D1N5
TSPGGQWWNFLREAT	EPHA1	661	P21709
PNSWNRQAGFRAWSS	DCANP1	191	Q8TF63
ACFSWGPWSRRKNQD	C2orf72	226	A6NCS6
PNWTAFSRWKTIGSL	CRYBG3	2816	Q68DQ2
FQSWWDRNLGRGSSA	BAD	151	Q92934
GRWEANWRNSASPSE	CFAP46	2531	Q8IYW2
PNSRVDDTFWASWRA	MIR22HG	6	Q0VDD5
WARPQSQWCPTGSRS	ACAD10	621	Q6JQN1
GREWSLESSPAQNWT	ARFGAP1	121	Q8N6T3
RSQVSKRTFWQGWQG	FAM186B	166	Q8IYM0
KRTFWQGWQGRSPQT	FAM186B	171	Q8IYM0
QPRSASEGIWWTVFF	ADCY5	321	O95622
SLQNWLNRHSWQRTP	CCNQ	151	Q8N1B3
RSARPQTGGTWESQW	ARMC10	61	Q8N2F6
SGQFQGRPSEVWSQW	ARNT2	646	Q9HBZ2
SWAWPTNHTGALARA	NXPH4	66	O95158
PLWAWFQRARVSSSD	RTN4RL2	271	Q86UN3
PARGAASWDTWRNKA	IQCN	891	Q9H0B3
RASGFYPWNITLSWR	MICA	226	Q29983
RSFRVGWGPNWTLAN	NUP98	1141	P52948
ARVGSRWTWLQAQIS	KANSL1L	376	A0AUZ9
NWSAWLTPFLRGTTR	NUDT19	196	A8MXV4
LGTNWSSSAAWLRQQ	NUDT22	91	Q9BRQ3
ASVPSQWRAVQGIRW	DYNC2I2	46	Q96EX3
PDGRSRWNTFNSLWD	ECE2	181	P0DPD6
PSNWTWVEGSGRLFS	ICAM5	581	Q9UMF0
GRQRASPGWQNWSSA	PDPR	11	Q8NCN5
QRSPNRWSSVFWKVG	NRSN1	51	Q8IZ57
GAWGNSAVSRPLEFW	LRBA	1966	P50851
SSQNNWLRTGFIWRR	EPHB3	86	P54753
SLWPWDSVRNNLRSA	MED17	91	Q9NVC6
SGQSFRWREQSPAHW	OGG1	41	O15527
RSGQRTASVLWPWIN	IRAK1	61	P51617
SNSAAWNWIRQSPSR	IGHV6-1	51	A0A0B4J1U7
RLRWRWFSHPFQGST	KLHL4	16	Q9C0H6
NRRETWLFSRFSTGW	HS6ST1	131	O60243
SGSTRLRWWQPSENG	RELN	2286	P78509
DALTNTTRLRWWQPF	RELN	3011	P78509
TTRLRWWQPFVISNG	RELN	3016	P78509
TNRIQPWSWQGSSLR	PKD1L2	1071	Q7Z442
SVWGSSRWLRASQPQ	QRFP	51	P83859
APRTQWRFGSWTPCS	ADAMTS9	1181	Q9P2N4
WRWEDGSPLNFSRIS	KLRG1	141	Q96E93
LSPWWRSSLTYFQQQ	KDM2B	841	Q8NHM5
SWLLFRSLQRAPSWS	DPH7	341	Q9BTV6
AQWGQNRERPWASSL	FRMPD2B	246	Q6IN97
QWGQNRERPWASSLT	FRMPD2	1236	Q68DX3
NNWLRTSWVPRDGAR	EPHA8	81	P29322
AFTQGWGSRRRWVTP	JMJD4	106	Q9H9V9
RRDISSWLAQWFPRT	CISD3	21	P0C7P0
SWLAQWFPRTPARSV	CISD3	26	P0C7P0
LVAWAVSNWGPNSAR	FUT6	191	P51993
SWRSPGRGSWFVQAL	CASP7	231	P55210
PSSFLRWLSQQTRWS	HAS1	366	Q92839
IWSTFSPSARWQRQD	MARCHF4	256	Q9P2E8
NQSRWNSGLRGLSWR	COMMD1	111	Q8N668
RTSAGWLPSFGRVWN	CENATAC	291	Q86UT8
RLFQPWSSLLRNWNS	CBL	246	P22681
WTWSGNSLTRKQGIF	EML4	436	Q9HC35
GRSRTKRSWVWNQFF	CDH7	41	Q9ULB5
WSNAGKYRWNSRPLS	FAM217A	371	Q8IXS0
WKPRVSNTVSGFWDF	FAM237A	61	A0A1B0GTK4
LDSSNPSWWTGRLHN	GRAP2	301	O75791
SFSRGSLKISWNPWR	PRRT3	906	Q5FWE3
FARNLQPGWTSWGNE	METTL4	441	Q8N3J2
GAGSWNKSRFLPQTW	LRRC43	46	Q8N309
VRDGTNVSYSWTAWR	PKD1	1656	P98161
WTVSGTPCREFWSRF	MRPL50	16	Q8N5N7
PQWRRSRSAQRWGRS	SRRM2	511	Q9UQ35
RISSWRNSTVTGHPW	OVCH1	46	Q7RTY7
WSYRPWNTTENEGSQ	KCNV2	11	Q8TDN2
WSRSLQLASWPNRGG	RNF26	291	Q9BY78
NYSRSWNDWQPRTDS	nan	16	Q6P435
TNSPWDSWASRGKLR	DIP2C-AS1	101	Q8N8Z3
WIRVQWDTGSTNSYR	HERC2P3	631	Q9BVR0
FGRNTQGSWRNEWLS	NPFF	76	O15130
NPTTWLANEAWRRFP	POM121L2	66	Q96KW2
RNPLNAGSWEWSDRT	PLA2R1	741	Q13018
QGRSTAWGLQDWSRP	STRC	1746	Q7RTU9
GVRFSWNVWPSSRLE	SEC23A	16	Q15436
GVRFSWNVWPSSRLE	SEC23B	16	Q15437
QATFWGLVTPRSWSC	SOAT2	506	O75908
QALPRWAAFTIWNAG	B3GNTL1	256	Q67FW5
QSWSWRRIPSEEASQ	ALK	286	Q9UM73
NRRFTLWWSPTINRA	PRPF8	1531	Q6P2Q9
NDSWRLWPSGDRSQQ	PAICS	211	P22234
GSRWRNFKQVFTWSG	ZDHHC6	266	Q9H6R6
NAGSRFLRSWTWPQT	MRPS11	6	P82912
FLRSWTWPQTAGRVV	MRPS11	11	P82912
ISWSGSNIRWGQAFR	RYR3	271	Q15413
SRPSFINRWNPWSTN	TPRG1L	171	Q5T0D9
PTRRDRKSWENSGFW	MYCBPAP	256	Q8TBZ2
RPRSIQRSWFGQFPW	ZNF862	461	O60290
RRRNPGWVSWSDSMQ	nan	86	Q8NA96
EERSWSNQRWSRATP	TCF23	46	Q7RTU1
WFTAQRLKQGISWSP	ZHX3	351	Q9H4I2
WTNSTIALRWTAPQG	PTPRH	486	Q9HD43
SWLTSSWNFNFPNIR	PRR11	56	Q96HE9
GSDWTPNAQFITRSW	MARS1	471	P56192
RWTWGDQTTLQGFLT	TMEM260	246	Q9NX78
WKRVGSQRPYWQNTS	ZAN	481	Q9Y493
TWRPRRSIVFASWGA	NAALADL1	401	Q9UQQ1